Skip to main content

Table 3 Binding of mAbs to subtype-A, B and C derived HIV-1 proteins and peptides

From: Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

  2anti-V3 mAbs  
1Protein/peptide Subtype I277 I903 I904 A447-52D 1418
Con-C V3 C 0.33 0.109 0.046 1.2 >10
Con-B V3 B >10 >10 0.623 0.323 >10
Du156.12 C 0.047 0.019 0.009 0.035 >10
JRFL B >10 >10 0.04 0.01 >10
92RW020 A 0.098 0.05 0.028 0.323 >10
SF162 B >10 >10 >10 0.004 >10
MN B >10 >10 2.27 0.011 >10
MPER C >10 >10 >10 >10 >10
IDR C >10 >10 >10 >10 >10
p24 B >10 >10 >10 >10 >10
BSA NA >10 >10 >10 >10 >10
PP NA >10 >10 >10 >10 >10
  1. 1List of recombinant proteins and peptides derived from subtype-A, B and C HIV-1 viruses, NA: Not applicable.
  2. 2Four anti-V3 antibodies, three from IndianI (277, 903 and 904) and one from AmericanA (447-52D) HIV-1 infected donor were tested for their relative binding. The binding activity of anti-V3 mAbs against proteins and peptides was tested by ELISA using mAbs at a concentration ranging from 10 to 0.00003 μg/ml (12 dilutions). The 50% binding titers (Max50, conc. μg/ml) of each antibody against the corresponding protein or peptide is depicted as numerical values in Bold (high affinity), Italic (low affinity) and >10, where Max50 value was not reached. Human anti-parvovirus B19 mAb 1418 was used as negative control. Each experiment was performed at least two independent times.